C Charpentier
Overview
Explore the profile of C Charpentier including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
205
Citations
1854
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Lambert-Niclot S, Grude M, Chaix M, Charpentier C, Reigadas S, Le Guillou-Guillemette H, et al.
J Antimicrob Chemother
. 2018 May;
73(8):2147-2151.
PMID: 29718247
Background: Atazanavir is a PI widely used as a third agent in combination ART. We aimed to determine the prevalence and the patterns of resistance in PI-naive patients failing on...
12.
Leroi A, Melchior C, Charpentier C, Bridoux V, Savoye-Collet C, Houivet E, et al.
Neurogastroenterol Motil
. 2018 Jan;
30(6):e13291.
PMID: 29345097
Background: The functional lumen imaging probe (EndoFLIP ) is a new technology that measures the distensibility of the anal canal represented by the anal distensibility index. The aims of this...
13.
Soulie C, Morand-Joubert L, Cottalorda J, Charpentier C, Bellecave P, Le Guen L, et al.
J Clin Virol
. 2018 Jan;
99-100:57-60.
PMID: 29331843
Objectives: There is no consensus about the performances of genotypic rules for predicting HIV-1 non-B subtype tropism. Three genotypic methods were compared for CRF01_AE HIV-1 tropism determination. Methods: The V3...
14.
Visseaux B, Damond F, Matheron S, Descamps D, Charpentier C
Infect Genet Evol
. 2018 Jan;
58:294.
PMID: 29307762
No abstract available.
15.
Delory T, Ferrand H, Grall N, Casalino E, Lafarge M, Melot B, et al.
Int J Tuberc Lung Dis
. 2018 Jan;
21(12):1272-1279.
PMID: 29297448
Objectives: To develop a diagnostic predictive model for the identification of patients with presumptive pulmonary tuberculosis (PTB) at high risk for active disease and those requiring nucleic acid amplification (NAAT)...
16.
Alessandri-Gradt E, Collin G, Tourneroche A, Bertine M, Leoz M, Charpentier C, et al.
J Antimicrob Chemother
. 2017 Sep;
72(9):2431-2437.
PMID: 28859447
Objectives: To determine natural phenotypic susceptibility of non-group M HIV-1 to integrase strand transfer inhibitors (INSTIs) in a large panel of 39 clinical strains from groups O, N and P...
17.
Todesco E, Charpentier C, Bertine M, Wirden M, Storto A, Desire N, et al.
HIV Med
. 2017 Apr;
18(9):696-700.
PMID: 28444829
Objectives: Transmitted drug resistance (TDR) can impair the response to first-line antiretroviral therapy. In treatment-naïve patients chronically infected with HIV type 1 (HIV-1), it was previously shown through Sanger sequencing...
18.
Assoumou L, Charpentier C, Recordon-Pinson P, Grude M, Pallier C, Morand-Joubert L, et al.
J Antimicrob Chemother
. 2017 Mar;
72(6):1769-1773.
PMID: 28333232
Background: Surveillance of HIV-1 resistance in treated patients with a detectable viral load (VL) is important to monitor, in order to assess the risk of spread of resistant viruses and...
19.
Marcelin A, Visseaux B, Wirden M, Morand-Joubert L, Soulie C, Charpentier C, et al.
J Glob Antimicrob Resist
. 2016 Nov;
2(2):103-106.
PMID: 27873586
To treat human immunodeficiency virus (HIV)-infected patients, international guidelines recommend the combination of two nucleos(t)ide reverse transcriptase inhibitors [N(t)RTIs] and a third agent [non-NRTI (NNRTI), boosted protease inhibitor (r/PI) or...
20.
Bocket L, Peytavin G, Alidjinou E, Ajana F, Choisy P, Le M, et al.
J Antimicrob Chemother
. 2016 May;
71(9):2651-3.
PMID: 27234463
Objectives: There are few data on clinical and virological factors associated with maraviroc virological response (VR) in clinical practice. This study aimed to identify factors associated with VR in 94...